


## Data Sheet

<b>Product Name:</b>	Formononetin
<b>Cat. No.:</b>	CS-3081
<b>CAS No.:</b>	485-72-3
<b>Molecular Formula:</b>	C <sub>16</sub> H <sub>12</sub> O <sub>4</sub>
<b>Molecular Weight:</b>	268.26
<b>Target:</b>	Apoptosis; FGFR
<b>Pathway:</b>	Apoptosis; Protein Tyrosine Kinase/RTK
<b>Solubility:</b>	DMSO : ≥ 35 mg/mL (130.47 mM)



### BIOLOGICAL ACTIVITY:

Formononetin is a potent **FGFR2** inhibitor with an **IC<sub>50</sub>** of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth<sup>[1]</sup>. **In Vitro:** Formononetin is one of the major isoflavonoid constituents isolated from *Astragalus membranaceus* and has been demonstrated diverse pharmacological benefits. Formononetin possesses anti-angiogenic activity in human colon cancer cells. Formononetin also promotes cell cycle arrest via downregulation of Akt/Cyclin D1/CDK4 in human prostate cancer cells<sup>[1]</sup>. Formononetin (25 to 150 μM) markedly decreases the proliferation of endothelial cells stimulated by FGF2<sup>[1]</sup>. **In Vivo:** Formononetin dramatically suppresses tumor volumes and the Formononetin-treated group tumor weight are significantly inhibited compared with the vehicle group. Formononetin treatment is well tolerated, and there is no significant difference in weight between vehicle group and formononetin treated groups<sup>[1]</sup>.

### References:

[1]. Xiao Yu Wu, et al. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models. *Oncotarget*. 2015 Dec 29;6(42):44563-78.

### CAIndexNames:

4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-methoxyphenyl)-

### SMILES:

O=C1C(C2=CC=C(OC)C=C2)=COC3=CC(O)=CC=C13

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA